Medical Oncology

, Volume 24, Issue 2, pp 197–201

Thymic epithelial neoplasia

A study of 58 cases
  • Emin Tamer Elkiran
  • Huseyin Abali
  • Sercan Aksoy
  • Kadri Altundag
  • Mustafa Erman
  • Ay§e Kars
  • Alev Turker
  • Gulten Tekuzman
  • Yavuz Ozisik
Original Article

Abstract

Primary thymic epithelial neoplasms (PTENs) are uncommon tumors of anterior mediastinum with a broad range of biological characteristics. We retrospectively reviewed 58 consecutive patients with a diagnosis of PTENs that were confirmed pathologically during 28 yr. There were 58 patients, 31 males (53.4%) and 27 females (46.6%), with a mean age of 43.6 ±13.8 yr (range, 17–73 yr). Twenty-one (36.2%) patients presented at the Masaoka stage I, 13 (22.4%) patient at stage II, 18 (31.0%) patient at stage III, and 6 (10.4%) patients at stage IV. Forty-five (77.7%) patients had myasthenia gravis, 1 (1.7%) immune deficiency, 1 (1.7%) pancytopenia, and 1 (1.7%) nephrotic syndrome. No paraneoplastic syndrome was associated in 10 (17.2%) patients. Complete resection was accomplished in 41 (70.7%) patients, while incomplete resection was performed in 8 (13.8%) patients. In nine (15.5%) patients only biopsy was carried out. Radiotherapy was administered to 19 (32.8%) patients. Eleven (19.0%) out of 58 who presented at advanced stages (at least III) received chemotherapy. Median follow-up period was 59 mo (range, 1-278 mo). During the follow-up period, 17 deaths occurred. Five patients (29.4%) died of tumor-related causes, and the remaining 12 patients died of other causes (cardiovascular diseases [n = 1, 5.9%], sepsis [n = 4, 23.5%], and MG-related respiratory insufficiency [n = 7, 41.2%]). The overall survival rates at 5 yr and 10 yr were 63.9% and 54.2%, respectively. Tumor-related survival rates at 5 yr and 10 yr were 89.0% and 83.2%, respectively. In our series, disease stage, presence or absence of myasthenia gravis, and tumor size did not affect survival (p> 0.05), either. Complete resection of the tumor seems to be the best predictive factor for long-term survival.

Key words

epithelial neoplasms paraneoplastic syndrome chemotherapy radiotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Thomas CR, Wright CD, Loehrer PJ. Thymoma: state of the art.J Clin Onco 1999;17(7):2280–2289.Google Scholar
  2. 2.
    Okumura M, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients.Cancer 2002; 94(3):624–632.PubMedCrossRefGoogle Scholar
  3. 3.
    Rios A, et al. Prognostic factors in thymic epithelial neoplasms.Eur J Cardiothorac Surg 2002;21(2):307–313.PubMedCrossRefGoogle Scholar
  4. 4.
    Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages.Cancer 1981;48(11):2485–2492.PubMedCrossRefGoogle Scholar
  5. 5.
    Johnson SB, Eng TY, Giaccone G, Thomas CR, Jr. Thymoma: update for the new millennium.Oncologist 2001;6(3):239–246.PubMedCrossRefGoogle Scholar
  6. 6.
    Hejna M, Haber I, Raderer M. Nonsurgical management of malignant thymoma.Cancer 1999;85(9):1871–1884.PubMedGoogle Scholar
  7. 7.
    Sonobe S, et al. Clinical usefulness of the WHO histological classification of thymoma.Ann Thorac Cardiovasc Surg 2005;11(6):367–373.PubMedGoogle Scholar
  8. 8.
    Okumura M, et al. Oncological significance of WHO histological thymoma classification. A clinical study based on 286 patients.Jpn J Thorac Cardiovasc Surg 2002;50(5):189–194.PubMedCrossRefGoogle Scholar
  9. 9.
    Loehrer PJ, Sr, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.Cancer 2001;91(11):2010–2015.PubMedCrossRefGoogle Scholar
  10. 10.
    Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, vanZandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.J Clin Oncol 1996;14(3):814–820.PubMedGoogle Scholar
  11. 11.
    Giaccone G. Treatment of malignant thymoma.Curr Opin Oncol 2005;17(2):140–146.PubMedCrossRefGoogle Scholar
  12. 12.
    Henley JD, Cummings OW, Loehrer PJ, Sr. Tyrosine kinase receptor expression in thymomas.J Cancer Res Clin Oncol 2004;130(4):222–224.PubMedCrossRefGoogle Scholar
  13. 13.
    Altundag K, Morandi P, Altundag O, Yigitbasi OG: Treatment of thymoma and prognostic factors: in regard to Zhu et al. (Int J Radiat Oncol Biol Phys 2004;60: 1113–1119).Int J Radiat Oncol Biol Phys 2005;62(3):942.CrossRefGoogle Scholar
  14. 14.
    Lardinois D, et al. Prognostic relevance of Masaoka and Muller-Hermelink classification in patients with thymic tumors.Ann Thorac Surg 2000;69(5):1550–1555.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2007

Authors and Affiliations

  • Emin Tamer Elkiran
    • 1
  • Huseyin Abali
    • 1
  • Sercan Aksoy
    • 1
  • Kadri Altundag
    • 1
  • Mustafa Erman
    • 1
  • Ay§e Kars
    • 1
  • Alev Turker
    • 1
  • Gulten Tekuzman
    • 1
  • Yavuz Ozisik
    • 1
  1. 1.Institute of Oncology, Department of Medical OncologyHacettepe UniversitySihhiyeTurkey

Personalised recommendations